WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (WO2008122037) INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY AS ADJUNCTS TO OPIATES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/122037    International Application No.:    PCT/US2008/059123
Publication Date: 09.10.2008 International Filing Date: 02.04.2008
IPC:
A61K 38/46 (2006.01)
Applicants: SAINT LOUIS UNIVERSITY [US/US]; 221 N. Grand Boulevard, St. Louis, MI 63103 (US) (For All Designated States Except US).
SALVEMINI, Daniela [US/US]; (US) (For US Only)
Inventors: SALVEMINI, Daniela; (US)
Agent: BUCKLEY, Kevin, W.; Spencer Fane Britt & Browne LLP, 1 North Brentwood Blvd., Suite 1000, St. Louis, MO 63105 (US)
Priority Data:
11/695,519 02.04.2007 US
Title (EN) INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY AS ADJUNCTS TO OPIATES
(FR) INHIBITEURS DE LA VOIE MÉTABOLIQUE DU CÉRAMIDE EN TANT QUE COMPLÉMENTS AUX OPIACÉS
Abstract: front page image
(EN)A method for inhibiting, reducing, or preventing antinociceptive/analgesic tolerance in a subject associated with the continued administration of opiates. Specifically, the method provides for administering agents, which reduce or prevent the increase in ceramide levels caused by administration of an opiate in a human or non-human subject. The method allows for improved pain management in subjects suffering from chronic pain and disorders associated with long term administration of opiates.
(FR)La présente invention concerne un procédé pour inhiber, réduire, ou prévenir la tolérance anti-nociceptive/analgésique chez un sujet, associé à l'administration continue d'opiacés. Spécifiquement, le procédé permet l'administration d'agents, qui réduisent ou préviennent l'augmentation des niveaux de céramide provoquée par l'administration d'un opiacé chez un sujet humain ou non humain. Le procédé permet une gestion de la douleur améliorée chez les sujets souffrant d'une douleur chronique et de troubles associés à une administration à long terme d'opiacés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)